ktn3379
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2014 (NCT02014909)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ERBB3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ktn3379
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02473731 | Phase 1 | Oct 1, 2015 | Celldex Therapeutics |
| NCT02456701 | Phase 1 | Jun 1, 2015 | Celldex Therapeutics, Cornell University |
| NCT02014909 | Phase 1 | Jan 1, 2014 | Celldex Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 3 | 3 | 1 | 2014 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1